Hypothesis Comparison

⚛ Collide these ⚔ Judge as Duel

Comparing 2 hypotheses side-by-side

|

STMN2 Cryptic Exon Inclusion is the Earliest Loss-of-Function Marker of TDP-43 N

TARDBP · ALS · mechanistic
Composite
0.702
Price
$0.50
Evidence For
0
Evidence Against
0

Loss of nuclear TDP-43 in ALS motor neurons first manifests as aberrant inclusion of the STMN2 cryptic exon 2a, producing a truncated non-functional STMN2 protein that impairs microtubule repair at the axon. This splicing defect precedes detectable cytoplasmic TDP-43 aggregation by at least 48h in iPSC motor neurons subjected to TDP-43 depletion, establishing STMN2 cryptic exon inclusion as the earliest measurable loss-of-function event. Restoring STMN2 function with antisense oligonucleotides s

Cross-Seeding Prevention Strategy

TARDBP · neurodegeneration · mechanistic
Composite
0.689
Price
$0.65
Evidence For
0
Evidence Against
0

## Mechanistic Overview Cross-Seeding Prevention Strategy starts from the claim that modulating TARDBP within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The cross-seeding prevention strategy targets the pathological interaction between TAR DNA-binding protein 43 (TDP-43), encoded by TARDBP, and classical neurodegenerative disease proteins such as amyloid-beta (Aβ), tau, and alpha-synucle

Convergent vs Divergent Predictions

This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.

TARDBPRna Splicing / Axon BiologyProtein Aggregation
Convergent signals
  • TARDBP recurs across 2 selected hypotheses with aligned directionality in RNA splicing / axon biology, protein aggregation.
Divergent signals
  • No direct polarity conflicts detected among the selected hypotheses.

Verdict Summary

4/11
dimensions won
STMN2 Cryptic Exon Inclusion is the Earl
8/11
dimensions won
Cross-Seeding Prevention Strategy

Radar Chart — 10 Dimensions

Score Comparison Bars

Mechanistic
0.94
0.72
Evidence
0.60
0.68
Novelty
0.55
0.55
Feasibility
0.75
0.64
Impact
0.88
0.71
Druggability
0.00
0.58
Safety
0.00
0.62
Competition
0.00
0.48
Data
0.00
0.75
Reproducible
0.00
0.59
KG Connect
0.50
0.79

Score Breakdown

DimensionSTMN2 Cryptic Exon Inclusion iCross-Seeding Prevention Strat
Mechanistic0.9400.720
Evidence0.6000.680
Novelty0.5500.550
Feasibility0.7500.640
Impact0.8800.710
Druggability0.0000.580
Safety0.0000.620
Competition0.0000.480
Data0.0000.750
Reproducible0.0000.590
KG Connect0.5000.788

Evidence

STMN2 Cryptic Exon Inclusion is the Earliest Loss-of-Functio

No evidence citations yet

Cross-Seeding Prevention Strategy

No evidence citations yet

Debate Excerpts

STMN2 Cryptic Exon Inclusion is the Earliest Loss-

4 rounds · quality: 0.67

Theorist

Theorist position for analysis 0ed3c364-07fd-4620-8e90-8bd33c14e370: Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons Source basis: Molecular Mechanisms of ...

Skeptic

Skeptic critique for analysis 0ed3c364-07fd-4620-8e90-8bd33c14e370: Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons The source paper motivates the gap, but...

Domain Expert

Domain expert assessment for analysis 0ed3c364-07fd-4620-8e90-8bd33c14e370: Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons The practical path is feasible ...

Synthesizer

{ "ranked_hypotheses": [ { "title": "RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation as proximal driver in Causal Sequence of TDP-43 ...

Cross-Seeding Prevention Strategy

4 rounds · quality: 0.92

Theorist

# Novel Therapeutic Hypotheses for RNA Binding Protein Dysregulation in Neurodegeneration ## 1. Stress Granule Phase Separation Modulators **Target:** G3BP1/2, TIA1, TIAR **Mechanism:** Pharmacologic...

Theorist

# Novel Therapeutic Hypotheses for RNA Binding Protein Dysregulation in Neurodegeneration ## 1. Stress Granule Phase Separation Modulators **Target:** G3BP1/2, TIA1, TIAR **Mechanism:** Pharmacologic...

Skeptic

# Critical Evaluation of RNA Binding Protein Therapeutic Hypotheses ## 1. Stress Granule Phase Separation Modulators **Specific Weaknesses:** - **Temporal specificity problem**: No evidence provided...

Skeptic

# Critical Evaluation of RNA Binding Protein Therapeutic Hypotheses ## 1. Stress Granule Phase Separation Modulators **Specific Weaknesses:** - **Temporal specificity problem**: No evidence provided...

Price History Overlay

Knowledge Graph Comparison

STMN2 Cryptic Exon Inclusion is the Earl

0 edges
Top Node Types
Top Relations

Cross-Seeding Prevention Strategy

72 edges
Top Node Types
gene58
hypothesis7
pathway6
protein1
Top Relations
co_discussed32
co_associated_with15
implicated_in7
participates_in4
regulates3

Pathway Diagrams

Curated mechanism pathway diagrams from expert analysis

Cross-Seeding Prevention Strategy

graph TD
    A["Cellular Stress Triggers"]
    B["TARDBP Gene Expression"]
    C["TDP-43 Protein Synthesis"]
    D["Nuclear TDP-43 Function"]
    E["Cytoplasmic TDP-43 Mislocalization"]
    F["TDP-43 Conformational Change"]
    G["Beta-Sheet Formation"]
    H["Cross-Seeding with Amyloid-beta"]
    I["Cross-Seeding with Tau Protein"]
    J["Cross-Seeding with Alpha-Synuclein"]
    K["Heterotypic Protein Aggregates"]
    L["Neuronal Dysfunction"]
    M["Synaptic Loss"]
    N["Neurodegeneration"]
    O["RNA Splicing Modulators"]
    P["Protein Disaggregation Therapy"]

    A -->|"induces"| B
    B -->|"transcribes"| C
    C -->|"maintains"| D
    A -->|"disrupts"| E
    C -->|"mislocalizes"| E
    E -->|"triggers"| F
    F -->|"promotes"| G
    G -->|"initiates"| H
    G -->|"initiates"| I
    G -->|"initiates"| J
    H -->|"forms"| K
    I -->|"forms"| K
    J -->|"forms"| K
    K -->|"causes"| L
    L -->|"leads to"| M
    M -->|"results in"| N
    O -->|"prevents"| E
    P -->|"dissolves"| K

    classDef mechanism fill:#4fc3f7
    classDef pathology fill:#ef5350
    classDef therapy fill:#81c784
    classDef outcome fill:#ffd54f
    classDef genetics fill:#ce93d8

    class A,F,G mechanism
    class E,H,I,J,K,L pathology
    class O,P therapy
    class M,N outcome
    class B,C,D genetics